Virtual-reality-assisted rehabilitation in the in-patient postoperative phase after Implantation of total knee and hip arthroplasties

Virtual-reality-assisted rehabilitation in the in-patient postoperative phase after Implantation of total knee and hip arthroplasties - VR-TEP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00039579

Enrollment

Registered

2026-04-23

Start date

2024-09-23

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after Implantation of total knee and hip arthroplasties

Interventions

Group 1: VR rehabilitation using the Pico Neo 4 VR headset, with the applications “SyncVR Relax & Distract” and “SyncVR Fit at Home,” for the duration of the inpatient stay. Study visits and data coll

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Indication for implantation of a total hip arthroplasty. Indication for implantation of a total knee arthroplasty. Sufficient knowledge of German to understand the informed consent process and complete the questionnaires, as well as the ability to actively participate in physiotherapeutic treatment and the virtual reality intervention.

Exclusion criteria

Exclusion criteria: Acute fracture of the bone to be operated on. Revision surgery. Prosthesis exchange. Cognitive disorders. Substance use disorders (e.g., alcohol or drug addiction). Incapacity to consent or limited legal capacity. Epilepsy.

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is the difference in pain intensity on the NRS (Numerical Rating Scale) between Visit 1 and Visit 3, measured in the intervention and control groups. For this purpose, pain intensity is assessed on the NRS at rest, during activity, and as an average. The primary analysis is based on the NRS at rest.	—

Secondary

Measure	Time frame
Secondary endpoints include the difference in pain intensity at various time points, at rest, during activity, and on average, between Visits 2 and 3, as well as between Visits 1 and 4 and Visits 1 and 5. Further secondary endpoints are the change in function and clinical outcome between Visit 1 and 4, based on the difference in the Knee Society Score and Harris Hip Score in the corresponding subgroups of patients who underwent knee or hip arthroplasty. In addition, the range of motion (ROM) of the knee joint is measured in the subgroup of patients who undergo knee arthroplasty as the difference between Visits 1 and 4. Based on this, changes in a pre-existing or newly occurring postoperative extension deficit are derived. Further secondary endpoints include patient satisfaction, analgesic requirements, and the use of walking aids at Visit 4. The use of rescue medication during the inpatient stay is also assessed.	—

Measure

Time frame

Secondary endpoints include the difference in pain intensity at various time points, at rest, during activity, and on average, between Visits 2 and 3, as well as between Visits 1 and 4 and Visits 1 and 5. Further secondary endpoints are the change in function and clinical outcome between Visit 1 and 4, based on the difference in the Knee Society Score and Harris Hip Score in the corresponding subgroups of patients who underwent knee or hip arthroplasty. In addition, the range of motion (ROM) of the knee joint is measured in the subgroup of patients who undergo knee arthroplasty as the difference between Visits 1 and 4. Based on this, changes in a pre-existing or newly occurring postoperative extension deficit are derived. Further secondary endpoints include patient satisfaction, analgesic requirements, and the use of walking aids at Visit 4. The use of rescue medication during the inpatient stay is also assessed.

—

Countries

Germany

Contacts

Public ContactWolfgang Ertel

Klinik für Orthopädische, Unfall -und Wiederherstellungschirurgie Campus Benjamin Franklin, Charité Universitätsmedizin Berlin

wolfgang.ertel@charite.de004930450515702

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026